Literature DB >> 8552282

Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells.

B R Sperber1, S Leight, M Goedert, V M Lee.   

Abstract

Hyperphosphorylated tau protein is the major constituent of the paired helical filament (PHF), the major fibrous component of the neurofibrillary lesions of Alzheimer's disease (AD). Hyperphosphorylation of tau is believed to be the critical event that leads to filament assembly. Identification of the responsible protein kinases is therefore a key step towards an understanding of the pathogenesis of AD. Mitogen-activated protein kinase, glycogen synthase kinase-3 (GSK3) and neuronal cdc2-like kinase have been shown to phosphorylate tau protein in vitro at a number of sites that are phosphorylated in PHFs. In this study, we report that transient transfection of human GSK3 beta into Chinese hamster ovary cells stably transfected with individual human tau isoforms leads to hyperphosphorylation of tau at all the sites investigated with phosphorylation-dependent anti-tau antibodies. Thus, GSK3 beta is a protein kinase that phosphorylates tau protein in intact cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8552282     DOI: 10.1016/0304-3940(95)11902-9

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  53 in total

1.  GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein.

Authors:  J J Credle; J L George; J Wills; V Duka; K Shah; Y-C Lee; O Rodriguez; T Simkins; M Winter; D Moechars; T Steckler; J Goudreau; D I Finkelstein; A Sidhu
Journal:  Cell Death Differ       Date:  2014-11-14       Impact factor: 15.828

2.  Deferiprone reduces amyloid-β and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet.

Authors:  Jaya R P Prasanthi; Matthew Schrag; Bhanu Dasari; Gurdeep Marwarha; April Dickson; Wolff M Kirsch; Othman Ghribi
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 3.  Initiating and growing an axon.

Authors:  F Polleux; William Snider
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04       Impact factor: 10.005

Review 4.  Targeting the endocannabinoid system in Alzheimer's disease.

Authors:  Jeremy Koppel; Peter Davies
Journal:  J Alzheimers Dis       Date:  2008-11       Impact factor: 4.472

5.  Experimental induction of type 2 diabetes in aging-accelerated mice triggered Alzheimer-like pathology and memory deficits.

Authors:  Jogender Mehla; Balwantsinh C Chauhan; Neelima B Chauhan
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

6.  Inositol hexakisphosphate kinase-1 regulates behavioral responses via GSK3 signaling pathways.

Authors:  A Chakraborty; C Latapy; J Xu; S H Snyder; J-M Beaulieu
Journal:  Mol Psychiatry       Date:  2013-02-26       Impact factor: 15.992

7.  Glycogen synthase kinase-3 is activated in neuronal cells by Galpha12 and Galpha13 by Rho-independent and Rho-dependent mechanisms.

Authors:  C Laura Sayas; Jesús Avila; Francisco Wandosell
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

8.  Hypothalamic glycogen synthase kinase 3β has a central role in the regulation of food intake and glucose metabolism.

Authors:  Jonas Benzler; Goutham K Ganjam; Manon Krüger; Olaf Pinkenburg; Maria Kutschke; Sigrid Stöhr; Juliane Steger; Christiane E Koch; Rebecca Ölkrug; Michael W Schwartz; Peter R Shepherd; David R Grattan; Alexander Tups
Journal:  Biochem J       Date:  2012-10-01       Impact factor: 3.857

9.  Dissociation of tau toxicity and phosphorylation: role of GSK-3beta, MARK and Cdk5 in a Drosophila model.

Authors:  Shreyasi Chatterjee; Tzu-Kang Sang; George M Lawless; George R Jackson
Journal:  Hum Mol Genet       Date:  2008-10-17       Impact factor: 6.150

Review 10.  Chaperone signalling complexes in Alzheimer's disease.

Authors:  John Koren; Umesh K Jinwal; Daniel C Lee; Jeffrey R Jones; Cody L Shults; Amelia G Johnson; Laura J Anderson; Chad A Dickey
Journal:  J Cell Mol Med       Date:  2009-04       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.